ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
Obesity diminishes response to immunotherapy in kidney cancer
In this study, the researchers looked at the interaction between [...]
ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy
A study presented during the 2020 American Society of Clinical [...]
The future of immunotherapy-based combinations for metastatic kidney cancer
The past decade or so has seen the development of [...]
Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone
A recent phase II clinical trial has shown that combined [...]
PD-L1 can be used to predict the likely course of kidney cancer
A recently published study evaluated the role of programmed-death receptor [...]
PD-1 and CTLA-4 as biomarkers for survival in kidney cancer
A recent study published in Journal of Clinical Medicine last [...]
PD-1, PD-L1 and PD-L2 levels differ between patients
In a recent study, published in BMC Cancer last month, [...]
Clinical significance of PD-1 and PD-L1 receptors in kidney cancer
A recent study, published in Cancer Science this month, suggests [...]
Potential biomarker for kidney cancer survival identified
A recent paper from researchers in China and published in [...]
